TEL AVIV - Entera Bio Ltd. (NASDAQ:ENTX) announced that multiple abstracts on its oral peptide pipeline have been accepted for ENDO 2026, the Endocrine Society’s annual meeting in Chicago from June 13-16, 2026.
The company, with a market cap of $58.6 million, has seen its stock drop 50% over six months to $1.19, though analysts maintain a $9 price target.
Clinical data supporting EB613 as a Phase 3 candidate for postmenopausal osteoporosis was selected for a late-breaking oral presentation on June 14, 2026.
Other presentations include EB612 for hypoparathyroidism and EB618 for obesity. Bond.az monitors these developments closely.
